These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 31611534)
1. Vonoprazan-associated Gastric Mucosal Redness: A Report of Four Cases. Kubo K; Kimura N; Matsuda S; Tsuda M; Mabe K; Kato M Intern Med; 2020 Feb; 59(4):507-511. PubMed ID: 31611534 [TBL] [Abstract][Full Text] [Related]
2. Vonoprazan-Associated Gastric Mucosal Redness in Non- Kubo K; Kimura N; Watanabe R; Higashino M; Tsuda M; Kato M Case Rep Gastroenterol; 2021; 15(2):751-758. PubMed ID: 34594176 [TBL] [Abstract][Full Text] [Related]
3. Parietal Cell Protrusions and Dilated Oxyntic Glands from Use of Vonoprazan. Miyamoto S; Matsuno Y; Kato M; Kudo T; Ono S; Shimizu Y; Sakamoto N Am J Gastroenterol; 2017 Dec; 112(12):1899-1901. PubMed ID: 29215611 [No Abstract] [Full Text] [Related]
4. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review. Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868 [TBL] [Abstract][Full Text] [Related]
5. Vonoprazan fumarate for the management of acid-related diseases. Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Vonoprazan for Helicobacter pylori Eradication. Kiyotoki S; Nishikawa J; Sakaida I Intern Med; 2020 Jan; 59(2):153-161. PubMed ID: 31243237 [TBL] [Abstract][Full Text] [Related]
7. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis. Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968 [TBL] [Abstract][Full Text] [Related]
8. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease. Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y Digestion; 2017; 95(4):281-287. PubMed ID: 28501868 [TBL] [Abstract][Full Text] [Related]
9. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors. Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A Digestion; 2017; 96(1):52-59. PubMed ID: 28662503 [TBL] [Abstract][Full Text] [Related]
10. Update on the Use of Vonoprazan: A Competitive Acid Blocker. Graham DY; Dore MP Gastroenterology; 2018 Feb; 154(3):462-466. PubMed ID: 29337157 [No Abstract] [Full Text] [Related]
11. Efficacy of Vonoprazan for Gastroesophageal Reflux Symptoms in Patients with Proton Pump Inhibitor-resistant Non-erosive Reflux Disease. Niikura R; Yamada A; Hirata Y; Hayakawa Y; Takahashi A; Shinozaki T; Takeuchi Y; Fujishiro M; Koike K Intern Med; 2018 Sep; 57(17):2443-2450. PubMed ID: 29607951 [TBL] [Abstract][Full Text] [Related]
12. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293 [TBL] [Abstract][Full Text] [Related]
13. Vonoprazan versus proton pump inhibitors for the management of gastroesophageal reflux disease: A protocol for a systematic review with meta-analysis. Kang H; Kim BJ; Choi G; Kim JG Medicine (Baltimore); 2018 Sep; 97(39):e12574. PubMed ID: 30278564 [TBL] [Abstract][Full Text] [Related]